Literature DB >> 8071011

Accrual of patients to randomized clinical trials. Factors affecting cancer prevention and control research.

A D Kaluzny1, L M Lacey, R Warnecke, J P Morrissey, E J Sondik, L Ford.   

Abstract

Clinical judgment is increasingly being challenged by the need for randomized clinical trials. The 1987 National Cancer Institute mandate--that the Community Clinical Oncology Program (CCOP) accrue patients to cancer control protocols--provided an opportunity to examine the factors that affect accrual performance. An analysis of 52 CCOPs and their research bases participating in the program found that the availability of protocols, involvement with research base activities, a demonstrated link to community physicians (particularly those physicians, such as surgeons, who had access to patients), and the use of personal contacts to inform non-CCOP physicians about CCOP activities were important facilitating factors for accruing patients to cancer prevention and control trials.

Entities:  

Mesh:

Year:  1994        PMID: 8071011     DOI: 10.1017/s0266462300006723

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  10 in total

1.  Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.

Authors:  Sara R Jacobs; Bryan J Weiner; Lori M Minasian; Marjorie J Good
Journal:  Contemp Clin Trials       Date:  2013-01-05       Impact factor: 2.226

Review 2.  Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program.

Authors:  Lori M Minasian; William R Carpenter; Bryan J Weiner; Darrell E Anderson; Worta McCaskill-Stevens; Stefanie Nelson; Cynthia Whitman; Joseph Kelaghan; Ann M O'Mara; Arnold D Kaluzny
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

3.  Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

Authors:  Bryan J Weiner; Sara R Jacobs; Lori M Minasian; Marjorie J Good
Journal:  J Oncol Pract       Date:  2012-05-01       Impact factor: 3.840

4.  Organizational and physician factors associated with patient enrollment in cancer clinical trials.

Authors:  Sara R Jacobs; Bryan J Weiner; Bryce B Reeve; Morris Weinberger; Lori M Minasian; Marjorie J Good
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

5.  Participation of Asian-American women in cancer chemoprevention research: physician perspectives.

Authors:  Tung T Nguyen; Carol P Somkin; Yifei Ma
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

6.  Accrual to the Breast Cancer Prevention Trial by participating Community Clinical Oncology Programs: a panel data analysis.

Authors:  C N Klabunde; A D Kaluzny
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

7.  Practice setting and physician influences on judgments of colon cancer treatment by community physicians.

Authors:  S L McFall; R B Warnecke; A D Kaluzny; L Ford
Journal:  Health Serv Res       Date:  1996-04       Impact factor: 3.402

8.  Determining the predictors of innovation implementation in healthcare: a quantitative analysis of implementation effectiveness.

Authors:  Sara R Jacobs; Bryan J Weiner; Bryce B Reeve; David A Hofmann; Michael Christian; Morris Weinberger
Journal:  BMC Health Serv Res       Date:  2015-01-22       Impact factor: 2.655

Review 9.  Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices.

Authors:  Shellie Ellis; Mugur Geana; Tomas Griebling; Charles McWilliams; Jessie Gills; Kelly Stratton; Christine Mackay; Ariel Shifter; Andrew Zganjar; Brantley Thrasher
Journal:  Trials       Date:  2019-10-07       Impact factor: 2.279

10.  Context matters: measuring implementation climate among individuals and groups.

Authors:  Sara R Jacobs; Bryan J Weiner; Alicia C Bunger
Journal:  Implement Sci       Date:  2014-04-17       Impact factor: 7.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.